LGL Partners’s Biogen BIIB Stock Holding History

LGL Partners’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-870	Closed	-$225K	–	105
2023 Q4	$225K	Hold	870	–	–	0.03%	90
2023 Q3	$224K	Hold	870	–	–	0.04%	88
2023 Q2	$248K	Hold	870	–	–	0.04%	88
2023 Q1	$242K	Hold	870	–	–	0.04%	85
2022 Q4	$241K	Sell	870 -267	-23%	-$75.4K	0.04%	85
2022 Q3	$304K	Sell	1,137 -26	-2%	-$5.52K	0.06%	93
2022 Q2	$237K	Hold	1,163	–	–	0.04%	88
2022 Q1	$245K	Sell	1,163 -11	-0.9%	-$2.39K	0.03%	90
2021 Q4	$282K	Hold	1,174	–	–	0.03%	85
2021 Q3	$332K	Hold	1,174	–	–	0.2%	66
2021 Q2	$407K	Sell	1,174 -120	-9%	-$36.4K	0.24%	57
2021 Q1	$362K	Hold	1,294	–	–	0.21%	62
2020 Q4	$317K	Hold	1,294	–	–	0.18%	70
2020 Q3	$367K	Hold	1,294	–	–	0.22%	58
2020 Q2	$346K	Sell	1,294 -134	-9%	-$40.3K	0.22%	61
2020 Q1	$452K	Buy	1,428 +40	+3%	+$12.1K	0.3%	45
2019 Q4	$412K	Hold	1,388	–	–	0.14%	60
2019 Q3	$323K	Buy	1,388 +215	+18%	+$50.1K	0.13%	74
2019 Q2	$274K	Buy	1,173 +50	+4%	+$11.5K	0.11%	90
2019 Q1	$265K	Buy	+1,123	New	+$354K	0.1%	89

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

LGL Partners's BIIB Position: Q1 2024 in Review

LGL Partners sold out of Biogen (BIIB) in Q1 2024, closing a stake of 870 shares — an estimated $225K sold.

LGL Partners first reported a position in BIIB in Q1 2019 and held it in 20 quarters. The position peaked at $452K in Q1 2020. 955 funds tracked by Wall St. Rank hold BIIB as of Q1 2024.

LGL Partners reported no remaining Biogen position as of Q1 2024 after selling out during the quarter.
LGL Partners sold 870 Biogen shares in Q1 2024, an estimated $225K.
LGL Partners first reported a position in Biogen in Q1 2019 and held it in 20 quarters.
LGL Partners's Biogen position peaked at $452K in Q1 2020.
955 funds tracked by Wall St. Rank held Biogen as of Q1 2024.

Based on LGL Partners's 13F filing for Q1 2024, filed 30 Apr 2024.